alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

32,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–25 of 57 studies with an author at Washington University in St. Louis (US) · tagged Treatments (page 1 of 3) · 32,180 in the whole library · How the 0–100 score works

Download bibliography of these 57 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 17,651 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Nature medicine 2024-02-21

With the emergence of Alzheimer's disease (AD) disease-modifying therapies, identifying patients who could benefit from these treatments becomes critical. 1 key finding →

Participants: 1,422 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 74 out of 100. Archives of neurology 1997-04-01

Furthermore, the dramatic and favorable effects on disturbing behaviors in AD suggest a novel approach for treatment of noncognitive symptoms. 1 key finding →

Participants: 343 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial

✓ Peer-reviewed alzhub usefulness score 73 out of 100. JAMA neurology 2020-02-01

Despite undetectable TPI-287 levels in CSF, CSF biomarkers demonstrated decreased chitinase-3-like protein-1 (YKL-40) levels in the 4RT treatment arm (mean [SD], -8.4 [26.0] ng/mL) compared with placebo (mean [SD], 10.4 [42.3] ng/mL; median difference, -14.6 [95% CI, -30.0 to 0.2] ng/mL; P = .048, Mann-Whitney test). 3 key findings →

Design: clinical trial Participants: 39 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Lecanemab Treatment in a Specialty Memory Clinic

✓ Peer-reviewed alzhub usefulness score 71 out of 100. JAMA Neurology 2025-07-01

The most significant adverse events associated with these therapies are infusion-related reactions and amyloid-related imaging abnormalities (ARIA) with edema/effusion (ARIA-E) and/or hemorrhage/hemosiderin deposition (ARIA-H). 5 key findings →

Design: cohort Participants: 234 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy

✓ Peer-reviewed alzhub usefulness score 70 out of 100. Archives of general psychiatry 2011-01-01

Donepezil and antidepressant therapy temporarily improved global cognition (treatment × time interaction, F₂,₂₁₆ = 3.78; P = .03), but effect sizes were small (Cohen d = 0.27, group difference at 1 year). 2 key findings →

Participants: 73 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Archives of neurology 2008-08-01

Group differences were seen in skin and subcutaneous tissue concerns (P=.05), including 3 possible drug rashes and 3 reports of hair color change in the treatment groups. 2 key findings →

Participants: 15 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

✓ Peer-reviewed alzhub usefulness score 69 out of 100. Neurology 2004-01-01

The failure of selective cyclo-oxygenase-2 inhibition to slow the progression of AD may indicate either that the disease process is too advanced to modify in patients with established dementia or that cyclo-oxygenase-2 does not play a significant role in the pathogenesis of the disorder. 5 key findings →

Participants: 692 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects

✓ Peer-reviewed alzhub usefulness score 66 out of 100. Alzheimer disease and associated disorders 2025-07-17

Etalanetug presented an adequate safety and immunogenicity profile in healthy adults. 3 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 58 out of 100. JAMA neurology 2022-03-01

In DIAD, clinical disease stage and BDNF Met66 were associated with cognitive impairment and levels of site-specific tau phosphorylation. 5 key findings →

Design: cohort study Participants: 527 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

✓ Peer-reviewed alzhub usefulness score 58 out of 100. Neurology 2007-03-01

For more than a decade, researchers have refined criteria for the diagnosis of dementia with Lewy bodies (DLB) and at the same time have recognized that cognitive impairment and dementia occur commonly in patients with Parkinson disease (PD). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Donanemab: Appropriate use recommendations

✓ Peer-reviewed alzhub usefulness score 58 out of 100. The journal of prevention of Alzheimer's disease 2025-03-27

Donanemab (Kisunla®), an IgG1 monoclonal antibody targeting N-terminal pyroglutamate-modified forms of amyloid-β, is approved in the United States for treatment of early symptomatic Alzheimer's disease (AD). 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Anti-amyloid treatments: Why we think they are worth it

✓ Peer-reviewed alzhub usefulness score 57 out of 100. Alzheimer's & dementia (New York, N. Y.) 2025-01-01

Years of experience watching our patients progressively decline and die from complications of Alzheimer's disease (AD) has strongly motivated us to provide newly approved anti-amyloid treatments to appropriate patients. 1 key finding →

Participants: 300 Evidence: low

Full summary, score breakdown and related studies → Original source

Biomarker-based staging of Alzheimer disease: rationale and clinical applications

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Nature reviews. Neurology 2024-03-01

Disease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The tau biomarker cascade is condensed in Down syndrome compared with sporadic Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 56 out of 100. Brain : a journal of neurology 2026-07-01

Characterizing the timing and progression of Alzheimer's disease biomarker onset in Down syndrome (DS) and contrasting potential timing differences with neurotypical adults is needed to identify optimal Alzheimer's disease therapeutic treatment windows in DS. 2 key findings →

Design: longitudinal study Participants: 198 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Sex-related Differences in Tau Positron Emission Tomography (PET) and the Effects of Hormone Therapy (HT)

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer disease and associated disorders 2021-04-01

Regional sex-related differences in tau PET burden may contribute to the disparities in AD prevalence between males and females. 4 key findings →

Design: cross-sectional Participants: 148 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2014-05-03

Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show any effect on disease progression in clinical trials, conceivably because the AD subjects are already too advanced to derive clinical benefit from treatment and because diagnosis based on clinical criteria alone introduces a high misdiagnosis rate. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Jump to any of the 3 pages

Page 2 Page 3

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 32,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 32,180 records, built mostly from automated pulls of Europe PMC (66.5% of the library) and OpenAlex (15.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,045 records (3.2% of the library) are not peer-reviewed — 966 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events

Last updated